Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial - PubMed
5 hours ago
- #lipid-lowering therapy
- #heterozygous familial hypercholesterolemia
- #obicetrapib
- Obicetrapib tested in patients with heterozygous familial hypercholesterolemia (HeFH) in the BROOKLYN randomized clinical trial.
- 354 patients (190 women, 164 men) with mean LDL cholesterol of 122 mg/dl were randomized (2:1) to obicetrapib 10 mg or placebo daily for 365 days.
- Primary endpoint: obicetrapib reduced LDL cholesterol by -36.3% (95% CI -42.2% to -30.4%, P < 0.0001) at day 84 compared to placebo.
- Secondary endpoints at day 84: reductions in apolipoprotein B (-24.4%), non-HDL cholesterol (-34.5%), and lipoprotein(a) (-45.9%), with an increase in HDL cholesterol (+138.7%).
- Obicetrapib was well tolerated, suggesting it is an effective therapy for additional lipid lowering in HeFH patients.
- Trial registration: ClinicalTrials.gov NCT05425745.